Patents by Inventor Geetha Thanga Mariappan

Geetha Thanga Mariappan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Milrinone controlled-release formulation
    Patent number: 11331274
    Abstract: The present invention relates to oral controlled-release formulations of 5-(pyridinyl)-2(1H)-pyridinone compounds and their use in the treatment of a subject with heart failure, a stage, class or manifestation of heart failure, or at risk of developing or exhibiting symptoms of heart failure. The formulations of the invention release the compounds in the range of between 0.1 ?g/kg body weight/minute and 20 ?g/kg body weight/minute.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: May 17, 2022
    Assignee: Baker Heart and Diabetes Institute
    Inventors: David Martin Kaye, Guy Krippner, Geetha Thanga Mariappan
  • Milrinone controlled-release formulation
    Patent number: 10736853
    Abstract: The present invention relates to oral controlled-release formulations of 5-(pyridinyl)-2(1H)-pyridinone compounds and their use in the treatment of a subject with heart failure, a stage, class or manifestation of heart failure, or at risk of developing or exhibiting symptoms of heart failure. The formulations of the invention release the compounds in the range of between 0.1 ?g/kg body weight/minute and 20 ?g/kg body weight/minute.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: August 11, 2020
    Assignee: Cardiora Pty Ltd.
    Inventors: David Martin Kaye, Guy Krippner, Geetha Thanga Mariappan
  • MILRINONE CONTROLLED-RELEASE FORMULATION
    Publication number: 20200146992
    Abstract: The present invention relates to oral controlled-release formulations of 5-(pyridinyl)-2(1H)-pyridinone compounds and their use in the treatment of a subject with heart failure, a stage, class or manifestation of heart failure, or at risk of developing or exhibiting symptoms of heart failure. The formulations of the invention release the compounds in the range of between 0.1 ?g/kg body weight/minute and 20 ?g/kg body weight/minute.
    Type: Application
    Filed: January 17, 2020
    Publication date: May 14, 2020
    Inventors: David Martin Kaye, Guy Krippner, Geetha Thanga Mariappan
  • Milrinone controlled-release formulation
    Patent number: 10537527
    Abstract: The present invention relates to oral controlled-release formulations of 5-(pyridinyl)-2(1H)-pyridinone compounds and their use in the treatment of a subject with heart failure, a stage, class or manifestation of heart failure, or at risk of developing or exhibiting symptoms of heart failure. The formulations of the invention release the compounds in the range of between 0.1 ?g/kg body weight/minute and 20 ?g/kg body weight/minute.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: January 21, 2020
    Assignee: Cardiora Pty Ltd.
    Inventors: David Martin Kaye, Guy Krippner, Geetha Thanga Mariappan
  • Uses of milrinone controlled-release formulation
    Patent number: 10517833
    Abstract: The present invention relates to oral controlled-release formulations of 5-(pyridinyl)-2(1H)-pyridinone compounds and their use in the treatment of a subject with heart failure, a stage, class or manifestation of heart failure, or at risk of developing or exhibiting symptoms of heart failure. The formulations of the invention release the compounds in the range of between 0.1 ?g/kg body weight/minute and 20 ?g/kg body weight/minute.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: December 31, 2019
    Assignee: Cardiora Pty Ltd.
    Inventors: David Martin Kaye, Guy Krippner, Geetha Thanga Mariappan
  • MILRINONE CONTROLLED-RELEASE FORMULATION
    Publication number: 20190091156
    Abstract: The present invention relates to oral controlled-release formulations of 5-(pyridinyl)-2(1H)-pyridinone compounds and their use in the treatment of a subject with heart failure, a stage, class or manifestation of heart failure, or at risk of developing or exhibiting symptoms of heart failure. The formulations of the invention release the compounds in the range of between 0.1 ?g/kg body weight/minute and 20 ?g/kg body weight/minute.
    Type: Application
    Filed: November 20, 2018
    Publication date: March 28, 2019
    Inventors: David Martin Kaye, Guy Krippner, Geetha Thanga Mariappan
  • Milrinone controlled-release formulation
    Patent number: 10137093
    Abstract: The present invention relates to oral controlled-release formulations of 5-(pyridinyl)-2(1H)-pyridinone compounds and their use in the treatment of a subject with heart failure, a stage, class or manifestation of heart failure, or at risk of developing or exhibiting symptoms of heart failure. The formulations of the invention release the compounds in the range of between 0.1 ?g/kg body weight/minute and 20 ?g/kg body weight/minute.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: November 27, 2018
    Assignee: Cardiora Pty Ltd.
    Inventors: David Martin Kaye, Guy Krippner, Geetha Thanga Mariappan
  • CONTROLLED-RELEASE FORMULATION
    Publication number: 20180325826
    Abstract: The present invention relates to oral controlled-release formulations of 5-(pyridinyl)-2(1H)-pyridinone compounds and their use in the treatment of a subject with heart failure, a stage, class or manifestation of heart failure, or at risk of developing or exhibiting symptoms of heart failure. The formulations of the invention release the compounds in the range of between 0.1 ?g/kg body weight/minute and 20 ?g/kg body weight/minute.
    Type: Application
    Filed: July 6, 2018
    Publication date: November 15, 2018
    Inventors: David Martin Kaye, Guy Krippner, Geetha Thanga Mariappan
  • CONTROLLED-RELEASE FORMULATION
    Publication number: 20140328908
    Abstract: The present invention relates to oral controlled-release formulations of 5-(pyridinyl)-2(1H)-pyridinone compounds and their use in the treatment of a subject with heart failure, a stage, class or manifestation of heart failure, or at risk of developing or exhibiting symptoms of heart failure. The formulations of the invention release the compounds in the range of between 0.1 ?g/kg body weight/minute and 20 ?g/kg body weight/minute.
    Type: Application
    Filed: August 16, 2012
    Publication date: November 6, 2014
    Applicant: Baker IDI Heart & Diabetes Institute Holdings Limited
    Inventors: David Martin Kaye, Guy Krippner, Geetha Thanga Mariappan